Four-year data support Endologix' Powerlink AAA (abdominal aortic aneurysm) stent graft system:
This article was originally published in Clinica
Executive Summary
Endologix says that four-year data are now available to support the durability of its Powerlink stent graft system for treating abdominal aortic aneurysms (AAAs). Follow-up results from the pivotal trial found that only 24 of the 192 patients treated with the minimally-invasive device required secondary procedures, the majority of which were for type II endoleak, indicating that the need for a secondary procedure was not device-specific, the Irvine, California firm said. In addition, 97.9% of the 53 patients followed for 48 months were free from AAA-related mortality and there were no reports of graft material failure. Powerlink was approved for sale in the US in October 2004.